Who
David Michael Johnson
Director
Company insider
Files Form 4 as: Director, Zentalis Pharmaceuticals; Director, Aura Biosciences.
In numbers
- Trades disclosed
- 58
- Buys
- 13
- Sells
- 3
- Bought
- $2.8M
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 7 Apr 2020
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,100 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 17 Jun 2025filed 18 Jun 2025 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —57,603 at $0.00 | filing |
| 16 May 2025filed 20 May 2025 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,000 | filing |
| 16 May 2025filed 20 May 2025 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $98K20,000 at $4.90 | filing |
| 21 Jun 2024filed 21 Jun 2024 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —48,429 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | AURA Aura Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,500 at $0.00 | filing |
| 20 Jun 2024filed 24 Jun 2024 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 10 Nov 2023filed 13 Nov 2023 | ZNTL Zentalis PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $168K17,000 at $9.88 | filing |
| 8 Nov 2023filed 9 Nov 2023 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $70K9,601 at $7.30 | filing |
| 8 Nov 2023filed 9 Nov 2023 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $73K10,000 at $7.30 | filing |
| 8 Nov 2023filed 9 Nov 2023 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $73K10,000 at $7.30 | filing |
| 7 Nov 2023filed 9 Nov 2023 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $545K76,000 at $7.17 | filing |
| 7 Nov 2023filed 9 Nov 2023 | AURA Aura BiosciencesBiotechnology | SEC FORM 4 Bought | $337K47,000 at $7.17 | filing |
News
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractZNTL · manilatimes.net · 18 Oct 2026
0 headlines in the last 90 days name David Michael Johnson; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.